Gefitinib enhances the anti-tumor immune response against EGFR-mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H

Gefitinib is a sensitive and effective drug to treat non-small-cell lung cancer (NSCLC) carrying the somatic activating mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR). In the present study, a new mechanism of action of gefitinib in EGFR-mutated NSCLC cells was dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Huihui, Zhang, Xilin, Xie, Shangzhi, Chen, Tianwei, Xie, Dong, Cai, Ying, Cui, Dawei, Wang, Liang, Chen, Wei, Wang, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581114/
https://www.ncbi.nlm.nih.gov/pubmed/36205136
http://dx.doi.org/10.3892/ijo.2022.5436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581114/
https://www.ncbi.nlm.nih.gov/pubmed/36205136
http://dx.doi.org/10.3892/ijo.2022.5436

Ejemplares similares